Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan.

Abstract

We investigated the relationship between hypertriglyceridemia and the single-nucleotide polymorphisms (SNPs) on APOA5 in human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) in Taiwan. Receipt of protease inhibitor-based HAART, high baseline triglyceride levels, and carriage of APOA5 SNP3 or c.553G>T variants or APOA5 SNP1T/SNP2G/SNP3C/c.553T haplotype were statistically significantly associated with development of extreme hypertriglyceridemia (triglyceride level, >500 mg/dL).

• Authors: Sui-Yuan Chang, Wei-Shin Ko, Jau-Tsuen Kao, Lan-Yang Chang, Hsin-Yun Sun, Mao-Yuan Chen, Szu-Min Hsieh, Wang-Huei Sheng, Shu-Fang Chang, Wen-Chun Liu, Cheng-Hsin Wu, Hui-Jen Hsu, Chuan-Liang Kao, Chun-Nan Lee, Chien-Ching Hung, Shan-Chwen Chang
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 48 Issue 6 Pg. 832-5 (Mar 15 2009) ISSN: 1537-6591 [Electronic] United States
• PMID: 19187029 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• APOA5 protein, human
• Apolipoprotein A-V
• Apolipoproteins A
• HIV Protease Inhibitors

Topics

• Adult
• Aged
• Aged, 80 and over
• Antiretroviral Therapy, Highly Active (adverse effects)
• Apolipoprotein A-V
• Apolipoproteins A (genetics)
• Female
• HIV Infections (drug therapy)
• HIV Protease Inhibitors (adverse effects, therapeutic use)
• Haplotypes
• Humans
• Hypertriglyceridemia (genetics)
• Male
• Middle Aged
• Point Mutation
• Polymorphism, Single Nucleotide
• Taiwan
• Young Adult